Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Human herpesvirus-6 viremia is not associated with poor clinical outcomes in children following allogeneic hematopoietic cell transplantation.

Violago L, Jin Z, Bhatia M, Rustia E, Kung AL, Foca MD, George D, Garvin JH, Sosna J, Robinson C, Karamehmet E, Satwani P.

Pediatr Transplant. 2015 Nov;19(7):737-44. doi: 10.1111/petr.12572. Epub 2015 Aug 29.

PMID:
26329541
2.

Heterogeneity of T Cell Responses to Pandemic pH1N1 Monovalent Vaccine in HIV-Infected Pregnant Women.

Weinberg A, Muresan P, Richardson K, Fenton T, Dominguez T, Bloom A, Watts DH, Abzug MJ, Nachman SA, Levin MJ; P1086 Study Team.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1170-7. doi: 10.1089/aid.2015.0151. Epub 2015 Aug 31.

3.

HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.

Harrison L, Melvin A, Fiscus S, Saidi Y, Nastouli E, Harper L, Compagnucci A, Babiker A, McKinney R, Gibb D, Tudor-Williams G; PENPACT-1 (PENTA 9PACTG 390) Study Team.

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):42-53. doi: 10.1097/QAI.0000000000000671.

PMID:
26322666
4.

Acute gastrointestinal graft-vs-host disease is associated with increased enteric bacterial bloodstream infection density in pediatric allogeneic hematopoietic cell transplant recipients.

Levinson A, Pinkney K, Jin Z, Bhatia M, Kung AL, Foca MD, George D, Garvin JH, Sosna J, Karamehmet E, Robinson C, Satwani P.

Clin Infect Dis. 2015 Aug 1;61(3):350-7. doi: 10.1093/cid/civ285. Epub 2015 May 5.

PMID:
25948061
5.

Effect of cytomegalovirus co-infection on normalization of selected T-cell subsets in children with perinatally acquired HIV infection treated with combination antiretroviral therapy.

Kapetanovic S, Aaron L, Montepiedra G, Anthony P, Thuvamontolrat K, Pahwa S, Burchett S, Weinberg A, Kovacs A; Pediatric AIDS Clinical Trials Group Protocol 366.

PLoS One. 2015 Mar 20;10(3):e0120474. doi: 10.1371/journal.pone.0120474. eCollection 2015.

6.

Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation.

Yin DE, Warshaw MG, Miller WC, Castro H, Fiscus SA, Harper LM, Harrison LJ, Klein NJ, Lewis J, Melvin AJ, Tudor-Williams G, McKinney RE Jr; PENPACT-1 (PENTA 9/PACTG 390) Study Team.

Pediatrics. 2014 Oct;134(4):e1104-16. doi: 10.1542/peds.2014-0527.

7.

Incidence rates of carbapenemase-producing Enterobacteriaceae clinical isolates in France: a prospective nationwide study in 2011-12.

Robert J, Pantel A, Mérens A, Lavigne JP, Nicolas-Chanoine MH; ONERBA's Carbapenem Resistance Study Group.

J Antimicrob Chemother. 2014 Oct;69(10):2706-12. doi: 10.1093/jac/dku208. Epub 2014 Jun 16.

8.

A multicenter study of initiation of antiretroviral therapy and transmitted drug resistance in antiretroviral-naive adolescents and young adults with HIV in New York City.

Gagliardo C, Brozovich A, Birnbaum J, Radix A, Foca M, Nelson J, Saiman L, Yin M, Carras-Terzian E, West E, Neu N.

Clin Infect Dis. 2014 Mar;58(6):865-72. doi: 10.1093/cid/ciu003. Epub 2014 Jan 14.

9.

Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1066 Study Team.

Clin Infect Dis. 2014 Feb;58(3):413-22. doi: 10.1093/cid/cit696. Epub 2013 Oct 21.

10.

Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life.

Yin MT, Lund E, Shah J, Zhang CA, Foca M, Neu N, Nishiyama KK, Zhou B, Guo XE, Nelson J, Bell DL, Shane E, Arpadi SM.

AIDS. 2014 Jan 28;28(3):345-53. doi: 10.1097/QAD.0000000000000070.

11.

High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088).

Weinberg A, Muresan P, Fenton T, Richardson K, Dominguez T, Bloom A, Petzold E, Anthony P, Cunningham CK, Spector SA, Nachman S, Siberry GK, Handelsman E, Flynn PM; IMPAACT P1088 study team.

Hum Vaccin Immunother. 2013 May;9(5):957-68. doi: 10.4161/hv.23774. Epub 2013 Jan 31.

12.

Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus.

Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ, Heckman B, Manzella A, Kabat B, Jean-Philippe P, Nachman S, Siberry GK; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1065 Protocol Team.

J Pediatr. 2012 Oct;161(4):676-81.e2. doi: 10.1016/j.jpeds.2012.04.005. Epub 2012 May 22.

13.
14.

Medication adherence in children and adolescents with HIV infection: associations with behavioral impairment.

Malee K, Williams P, Montepiedra G, McCabe M, Nichols S, Sirois PA, Storm D, Farley J, Kammerer B; PACTG 219C Team.

AIDS Patient Care STDS. 2011 Mar;25(3):191-200. doi: 10.1089/apc.2010.0181. Epub 2011 Feb 16.

15.

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

PENPACT-1 (PENTA 9/PACTG 390) Study Team, Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, Harper L, Harrison L, Hughes M, McKinney R, Melvin A, Mofenson L, Saidi Y, Smith ME, Tudor-Williams G, Walker AS.

Lancet Infect Dis. 2011 Apr;11(4):273-83. doi: 10.1016/S1473-3099(10)70313-3. Epub 2011 Jan 31.

16.

Early increases in concentrations of total, LDL, and HDL cholesterol in HIV-infected children following new exposure to antiretroviral therapy.

Sztam KA, Jiang H, Jurgrau A, Deckelbaum RJ, Foca MD.

J Pediatr Gastroenterol Nutr. 2011 Apr;52(4):495-8. doi: 10.1097/MPG.0b013e3181f5e9d4.

PMID:
21206378
17.

Associations of proinflammatory cytokine levels with lipid profiles, growth, and body composition in HIV-infected children initiating or changing antiretroviral therapy.

Cervia JS, Chantry CJ, Hughes MD, Alvero C, Meyer WA 3rd, Hodge J, Borum P, Moye J Jr, Spector SA; PACTG 1010 Team.

Pediatr Infect Dis J. 2010 Dec;29(12):1118-22. doi: 10.1097/INF.0b013e3181ed9f4c.

18.

Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.

Siberry GK, Williams PL, Lujan-Zilbermann J, Warshaw MG, Spector SA, Decker MD, Heckman BE, Demske EF, Read JS, Jean-Philippe P, Kabat W, Nachman S; IMPAACT P1065 Protocol Team.

Pediatr Infect Dis J. 2010 May;29(5):391-6. doi: 10.1097/INF.0b013e3181c38f3b.

19.

Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapy.

Chantry CJ, Cervia JS, Hughes MD, Alvero C, Hodge J, Borum P, Moye J Jr; PACTG 1010 Team.

HIV Med. 2010 Oct 1;11(9):573-83. doi: 10.1111/j.1468-1293.2010.00823.x. Epub 2010 Mar 21.

20.

Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

Williams PL, Marino M, Malee K, Brogly S, Hughes MD, Mofenson LM; PACTG 219C Team.

Pediatrics. 2010 Feb;125(2):e250-60. doi: 10.1542/peds.2009-1112. Epub 2010 Jan 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk